Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0E8HA
|
|||
| Former ID |
DNCL001994
|
|||
| Drug Name |
T-817MA
|
|||
| Synonyms |
Edonerpic maleate; T-817MA; UNII-0LB9F7I5P3; 0LB9F7I5P3; 519187-97-4; T-817; T-817 maleate; SCHEMBL48064; RLUCYBFCLXANSO-BTJKTKAUSA-N; HY-17631A; DC10762; CS-8069; J2.179.155E; 1-(3-(2-(1-benzothiophen-5-yl)ethoxy)propyl)azetidin-3-ol maleate; 1-{3-[2-(1-benzothiophen-5-yl)ethoxy]propyl}-3-azetidinol maleate; 1-(3-(2-(Benzo(b)thiophene-5-yl)ethoxy)propyl)azetidine-3-ol maleate; 1-(3-(2-(1-benzothiophene-5-yl)ethoxy)propyl)-3-azetidinol maleate; 3-Azetidinol, 1-(3-(2-benzo(b)thien-5-ylethoxy)propyl)-, (2Z)-2-butenedioate (1:
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Alzheimer disease [ICD-11: 8A20; ICD-10: G30, G30.9; ICD-9: 331] | Phase 2 | [1] | |
| Company |
Toyama Chemical
|
|||
| Structure |
 |
Download2D MOL |
||
| Formula |
C20H25NO6S
|
|||
| Canonical SMILES |
C1C(CN1CCCOCCC2=CC3=C(C=C2)SC=C3)O.C(=CC(=O)O)C(=O)O
|
|||
| InChI |
1S/C16H21NO2S.C4H4O4/c18-15-11-17(12-15)6-1-7-19-8-4-13-2-3-16-14(10-13)5-9-20-16;5-3(6)1-2-4(7)8/h2-3,5,9-10,15,18H,1,4,6-8,11-12H2;1-2H,(H,5,6)(H,7,8)/b;2-1-
|
|||
| InChIKey |
RLUCYBFCLXANSO-BTJKTKAUSA-N
|
|||
| CAS Number |
CAS 519187-97-4
|
|||
| PubChem Compound ID | ||||
| PubChem Substance ID | ||||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Amyloid beta A4 protein (APP) | Target Info | Inhibitor | [2], [3] |
| Lipid peroxidation (LPO) | Target Info | Modulator | [4] | |
| KEGG Pathway | Notch signaling pathway | |||
| Alzheimer's disease | ||||
| Reactome | Nuclear signaling by ERBB4 | |||
| Degradation of the extracellular matrix | ||||
| Regulated proteolysis of p75NTR | ||||
| NRIF signals cell death from the nucleus | ||||
| Activated NOTCH1 Transmits Signal to the Nucleus | ||||
| Constitutive Signaling by NOTCH1 PEST Domain Mutants | ||||
| Constitutive Signaling by NOTCH1 HD+PEST Domain Mutants | ||||
| EPH-ephrin mediated repulsion of cells | ||||
| WikiPathways | Notch Signaling Pathway | |||
| Signaling by ERBB4 | ||||
| Signaling by NOTCH3 | ||||
| Signaling by NOTCH4 | ||||
| Signaling by NOTCH1 | ||||
| Signaling by NOTCH2 | ||||
| Notch Signaling Pathway | ||||
| Alzheimers Disease | ||||
| Signalling by NGF | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT02079909) Efficacy and Safety of T-817MA in Patients With Mild to Moderate Alzheimer's Disease (US202). U.S. National Institutes of Health. | |||
| REF 2 | Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) | |||
| REF 3 | Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) | |||
| REF 4 | A neuroprotective agent, T-817MA (1-{3-[2-(1-benzothiophen-5-yl)ethoxy]propyl} azetidin-3-ol maleate), prevents 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced neurotoxicity in mice. Neuropharmacology. 2008 Oct;55(5):654-60. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.